首页> 外文期刊>Tumori. >Combined chemoradiation for head and neck region myxofibrosarcoma of the maxillary sinus.
【24h】

Combined chemoradiation for head and neck region myxofibrosarcoma of the maxillary sinus.

机译:联合化学放射治疗上颌窦的头颈部区域黏膜纤维肉瘤。

获取原文
获取原文并翻译 | 示例
           

摘要

Adult sarcomas of the head and neck region (HNSs) are considered a rare clinicopathological entity. They account for only 2-15% of all adult sarcomas and for less than 1% of all head and neck malignancies. The preferred initial treatment option is wide surgical excision. Whenever surgery is considered infeasible, a frontline combined-modality approach including radiotherapy and chemotherapy might be proposed. We here report on a case of localized sarcoma of the maxillary sinus treated with induction chemotherapy and subsequent intensity-modulated radiation therapy (IMRT), achieving a persistent complete remission status.A 66-year-old man was referred to our institution hospital for left-sided facial pain with swollen left cheek and ipsilateral facial palsy. Magnetic resonance imaging showed a mass within the left maxillary sinus extending to the orbital floor and adjacent alveolar bones. Histological examination of the biopsy specimen demonstrated a myxofibrosarcoma. The patient underwent induction chemotherapy with gemcitabine 900 mg/m2 (days 1-8) and taxotere 80 mg/m2 every 3 weeks for 3 cycles and sequential simultaneous integrated boost (SIB) IMRT up to a total dose of 70 Gy/35 fractions to the macroscopic disease with 59.5 Gy/35 fractions to the level IB-II lymph nodes in the left neck.Treatment was well tolerated with mild acute toxicity. Complete remission was achieved at restaging MRI 6 months after the end of the combined modality approach. The patient remains in complete, unmaintained clinical and instrumental complete remission 18 months after treatment, with no late side effects.Combination therapy with induction chemotherapy and sequential SIB-IMRT could therefore be a promising modality for head and neck sarcomas, allowing for simultaneous tumor control and normal tissue sparing.
机译:头颈部区域(HNS)的成人肉瘤被认为是一种罕见的临床病理实体。它们仅占所有成人肉瘤的2-15%,并且不到所有头颈部恶性肿瘤的1%。首选的初始治疗选择是广泛的手术切除。只要认为手术不可行,就可能建议采用包括放射疗法和化学疗法在内的前线联合方式。我们在此报告一例上颌窦局部肉瘤,通过诱导化学疗法和随后的调强放射治疗(IMRT)进行治疗,实现了持续的完全缓解状态.66岁的一名男子被转介到我们机构的医院,因左面部疼痛伴左脸肿胀和同侧面部麻痹。磁共振成像显示左上颌窦内的肿块延伸到眶底和邻近的牙槽骨。活检标本的组织学检查显示为黏膜纤维肉瘤。该患者每3周接受900 mg / m2吉西他滨(第1-8天)和泰索帝80 mg / m2的诱导化疗,共3个周期,并依次同时进行综合增强(SIB)IMRT,总剂量为70 Gy / 35馏分至宏观疾病,左颈IB-II淋巴结水平为59.5 Gy / 35分数。治疗耐受性良好,有轻度急性毒性。联合方式治疗结束后6个月重新进行MRI复查,完全缓解。患者在治疗后18个月仍处于完全,未维护的临床和器械完全缓解状态,无晚期副作用,因此,诱导化疗与序贯SIB-IMRT联合治疗可能是头颈部肉瘤的一种有前途的治疗方式,从而可以同时控制肿瘤和正常的组织备用。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号